Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV001706715 | SCV001934469 | pathogenic | Bohring-Opitz syndrome | 2021-03-05 | criteria provided, single submitter | clinical testing | This variant was identified as de novo (maternity and paternity confirmed). |
Ce |
RCV001726412 | SCV001962380 | pathogenic | not provided | 2023-04-01 | criteria provided, single submitter | clinical testing | ASXL1: PVS1:Strong, PM2, PS2:Moderate, PS4:Moderate |
Center for Genomic Medicine, |
RCV001706715 | SCV004808274 | likely pathogenic | Bohring-Opitz syndrome | 2024-03-29 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001706715 | SCV005204835 | pathogenic | Bohring-Opitz syndrome | 2024-06-10 | criteria provided, single submitter | clinical testing | Variant summary: ASXL1 c.1900_1922del23 (p.Glu635ArgfsX15) results in a premature termination codon, not expected to result in nonsense mediated decay (NMD) but predicted to cause a truncation of the encoded protein, removing a large part of the protein, including the PHD-type zinc finger domain (amino acids 1500-1539; IPR026905), which is a DNA-binding domain. The frequency data for this variant in gnomAD is considered unreliable, as metrics indicate poor data quality at this position. To our knowledge, the variant, c.1900_1922del23, has not been reported in the literature in individuals affected with Bohring-Opitz Syndrome. However, multiple truncations downstream are reported in affected individuals (HGMD) and are classified as pathogenic for Bohring-Opitz syndrome by our laboratory (and others in ClinVar). ClinVar contains an entry for this variant (Variation ID: 812900). Based on the evidence outlined above, the variant was classified as pathogenic. |
NIHR Bioresource Rare Diseases, |
RCV001003812 | SCV001162262 | pathogenic | Juvenile myelomonocytic leukemia; Cafe-au-lait spot | no assertion criteria provided | research |